340 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded http://www.zacks.com/stock/news/253183/pharma-stock-roundup-astrazenecas-lynparza-impresses-in-study-merck-drug-label-expanded?cid=CS-ZC-FT-253183 Mar 17, 2017 - Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.
Allergan (AGN) and Editas Tie Up to Treat Eye Diseases http://www.zacks.com/stock/news/252926/allergan-agn-and-editas-tie-up-to-treat-eye-diseases?cid=CS-ZC-FT-252926 Mar 15, 2017 - Allergan plc's (AGN), and Editas Medicine, Inc. (EDIT), entered into a strategic research and development agreement.
Allergan (AGN) Enters Strategic Alliance With Editas Medicine (EDIT) - Slideshow http://seekingalpha.com/article/4055538-allergan-agn-enters-strategic-alliance-editas-medicine-edit-slideshow?source=feed_sector_healthcare Mar 15, 2017 - The following slide deck was published by Allergan plc in conjunction with this event.
Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise http://www.zacks.com/stock/news/252545/acordas-four-ampyra-patents-upheld-by-ptab-shares-rise?cid=CS-ZC-FT-252545 Mar 13, 2017 - U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld four patents of Acorda's key growth driver, Ampyra.
Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction http://www.zacks.com/stock/news/252531/aerie-resubmits-rhopressa-nda-roclatan-gains-traction?cid=CS-ZC-FT-252531 Mar 13, 2017 - Aerie Pharmaceuticals is a development-stage company focused on the development and commercialization of eye disease therapies, including glaucoma and other eye-diseases.
Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release? http://www.zacks.com/stock/news/252447/why-amgen-amgn-stock-rallied-after-q4-earnings-release?cid=CS-ZC-FT-252447 Mar 10, 2017 - Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.
Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA http://www.zacks.com/stock/news/252294/allergans-agn-vraylar-snda-accepted-for-review-by-fda?cid=CS-ZC-FT-252294 Mar 09, 2017 - Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.
Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted http://www.zacks.com/stock/news/252134/aerie-aeri-q4-loss-widens-rhopressa-nda-resubmitted?cid=CS-ZC-FT-252134 Mar 08, 2017 - Aerie Pharmaceuticals, Inc. (AERI) posted fourth-quarter 2016 loss of 87 cents per share (including stock-based compensation), wider than both the Zacks Consensus Estimate of a loss of 65 cents
Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs http://www.zacks.com/stock/news/252108/trump-tweet-on-drug-pricing-hits-biotech-and-pharma-etfs?cid=CS-ZC-FT-252108 Mar 08, 2017 - President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.
Pharma Industry Outlook - February/March 2017 http://www.zacks.com/commentary/104804/pharma-industry-outlook-february-march-2017?cid=CS-ZC--104804 Feb 27, 2017 - Pharma Industry Outlook - February/March 2017

Pages: 1...262728293031323334

<<<Page 31>